Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Alto Neuroscience presented positive Phase 2a data for ALTO-207 in Major Depressive Disorder, showing statistically significant reductions in depressive symptoms versus placebo at Week 6 and Week 8. The trial demonstrated robust effect sizes (Cohen's d=1.67 at Week 6) and favorable tolerability, validating the drug's mechanism of pairing pramipexole with ondansetron to enable higher, more effective dosing.
Key figures
- Drug Name
- ALTO-207
- Phase Of Trial
- Phase 2a
- Mean dose mg
- 4.1
- Patients enrolled
- 32
- P value madrs week6
- 0.0004
- P value madrs week8
- 0.025
- Effect size madrs week6
- 1.67
- Effect size madrs week8
- 1.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.